发明名称 Heterocyclic compound
摘要 The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I):; wherein each symbol is as defined in the specification, or a salt thereof.
申请公布号 US9321757(B2) 申请公布日期 2016.04.26
申请号 US201414533326 申请日期 2014.11.05
申请人 Takeda Pharmaceutical Company Limited 发明人 Yoshida Masato;Takami Kazuaki;Tominari Yusuke;Shiokawa Zenyu;Shibuya Akito;Sasaki Yusuke;Gibson Tony;Takagi Terufumi
分类号 C07D401/14;C07D487/04;C07D417/14;C07D487/10;A61P37/00;C07D403/14;A61K31/4155;C07D413/14;C07D409/14;C07D405/14;C07D401/04;A61K9/06;A61K9/20;A61K9/48 主分类号 C07D401/14
代理机构 Foley & Lardner LLP 代理人 Foley & Lardner LLP
主权项 1. A compound represented by the formula (I): wherein R1 is an aromatic heterocyclic group or a C6-14 aryl group, each of which is optionally substituted by 1 to 3 substituents selected from (1) a halogen atom, (2) a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A, (3) a C6-14 aryl group optionally having substituent(s) selected from Substituent Group A, (4) a heterocyclic group optionally having substituent(s) selected from Substituent Group A and a thioxo group (the substituent is optionally further substituted by substituent(s) selected from Substituent Group A, an azido group and a mono- or di-C1-6 alkylamino group (the alkyl is substituted by substituent(s) selected from a C3-10 cycloalkyl group and a halogen atom)), (5) a C3-10 cycloalkylsulfonyl group, (6) a C1-6 alkyl-carbonyl group, (7) an aromatic heterocyclylsulfonyl group, and (8) a halogenated sulfanyl group; R2 is (1) a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A, and a non-aromatic heterocyclic group having oxo group(s), (2) a C3-10 cycloalkyl group optionally having substituent(s) selected from Substituent Group A, or (3) a non-aromatic heterocyclic group optionally having substituent(s) selected from Substituent Group A; R3 and R4 are independently a hydrogen atom or a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A;R5 and R6 are independently (1) a hydrogen atom, (2) a hydroxy group, (3) a C1-6 alkyl group optionally having substituent(s) selected from (1) Substituent Group A, and (2) an amino group mono- or di-substituted by substituent(s) selected from (a) a C1-6 alkyl group, (b) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, (c) a non-aromatic heterocyclic group, (d) a C1-6 alkylsulfonyl group, and (e) a C3-10 cycloalkyl-carbonyl group, (4) a C1-6 alkoxy group optionally having substituent(s) selected from Substituent Group A, (5) an amino group optionally mono- or di-substituted by substituent(s) selected from (i) a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A, (ii) a C1-6 alkyl-carbonyl group optionally having substituent(s) selected from Substituent Group A, and (iii) a C1-6 alkylsulfonyl group optionally having substituent(s) selected from Substituent Group A, (6) a non-aromatic heterocyclic group optionally having substituent(s) selected from Substituent Group A, (7) a carboxy group, or (8) a carbamoyl group optionally mono- or di-substituted by C1-6 alkyl group(s), or R5 and R6 in combination optionally form (1) a non-aromatic heterocycle optionally having substituent(s) selected from Substituent Group A, or (2) a C3-10 cycloalkane optionally having substituent(s) selected from Substituent Group A; X is CR7R8, NR9, O or S;R7 and R8 are independently (1) a hydrogen atom, (2) a cyano group, (3) a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A, or (4) a hydroxy group, or R7 and R8 in combination optionally form (1) a C3-10 cycloalkane optionally having substituent(s) selected from Substituent Group A, or (2) a non-aromatic heterocycle optionally having substituent(s) selected from Substituent Group A and a C7-16 aralkyl group; and R9 is (1) a hydrogen atom, (2) a C1-6 alkyl group optionally having substituent(s) selected from Substituent Group A, (3) a C2-6 alkenyl group optionally having substituent(s) selected from Substituent Group A, or (4) a C7-16 aralkyl group optionally having substituent(s) selected from Substituent Group A, or a salt thereof; wherein Substituent Group A consists of (1) a halogen atom, (2) a nitro group, (3) a cyano group, (4) an oxo group, (5) a hydroxy group, (6) an optionally halogenated C1-6 alkoxy group, (7) a C6-14 aryloxy group, (8) a C7-16 aralkyloxy group, (9) a 5- to 14-membered aromatic heterocyclyloxy group, (10) a 3- to 14-membered non-aromatic heterocyclyloxy group, (11) a C1-4 alkyl-carbonyloxy group, (12) a C6-14 aryl-carbonyloxy group, (13) a C3-6 alkoxy-carbonyloxy group, (14) a mono- or di-C1-6 alkyl-carbamoyloxy group, (15) a C6-14 aryl-carbamoyloxy group, (16) a 5- to 14-membered aromatic heterocyclylcarbonyloxy group, (17) a 3- to 14-membered non-aromatic heterocyclylcarbonyloxy group, (18) an optionally halogenated C1-6 alkylsulfonyloxy group, (19) a C6-14 arylsulfonyloxy group optionally substituted by a C1-6 alkyl group, (20) an optionally halogenated C1-6 alkylthio group, (21) a 5- to 14-membered aromatic heterocyclic group, (22) a 3- to 14-membered non-aromatic heterocyclic group, (23) a formyl group, (24) a carboxy group, (25) an optionally halogenated C1-6 alkyl-carbonyl group, (26) a C6-14 aryl-carbonyl group, (27) a 5- to 14-membered aromatic heterocyclylcarbonyl group, (28) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, (29) a C1-6 alkoxy-carbonyl group, (30) a C6-14 aryloxy-carbonyl group, (31) a C7-16 aralkyloxy-carbonyl group, (32) a carbamoyl group, (33) a thiocarbamoyl group, (34) a mono- or di-C1-6 alkyl-carbamoyl group, (35) a C6-14 aryl-carbamoyl group, (36) a 5- to 14-membered aromatic heterocyclylcarbamoyl group, (37) a 3- to 14-membered non-aromatic heterocyclylcarbamoyl group, (38) an optionally halogenated C1-6 alkylsulfonyl group, (39) a C6-14 arylsulfonyl group, (40) a 5- to 14-membered aromatic heterocyclylsulfonyl group, (41) an optionally halogenated C1-6 alkylsulfinyl group, (42) a C6-14 arylsulfinyl group, (43) a 5- to 14-membered aromatic heterocyclylsulfinyl group, (44) an amino group, (45) a mono- or di-C1-6 alkylamino group, (46) a mono- or di-C6-14 arylamino group, (47) a 5- to 14-membered aromatic heterocyclylamino group, (48) a C7-16 aralkylamino group, (49) a formylamino group, (50) a C1-6 alkyl-carbonylamino group, (51) a (C1-6 alkyl)(C1-6 alkyl-carbonyl)amino group, (52) a C6-14 aryl-carbonylamino group, (53) a C1-6 alkoxy-carbonylamino group, (54) a C7-16 aralkyloxy-carbonylamino group, (55) a C1-6 alkylsulfonylamino group, (56) a C6-14 arylsulfonylamino group optionally substituted by a C1-6 alkyl group, (57) an optionally halogenated C1-6 alkyl group, (58) a C2-6 alkenyl group, (59) a C2-6 alkenyl group, (60) a C3-10 cycloalkyl group, (61) a C3-10 cycloalkenyl group and (62) a C6-14 aryl group.
地址 Osaka JP
您可能感兴趣的专利